Table 3.

NPSI Pain outcome scores for active treatment group and placebo group at baseline, 4 and 8 weeks

Outcome	Group	Baseline	P value	4 weeks	P value	Change at 4 weeks	Effect size [95% CI]	8 weeks	P value	Change at 8 weeks	Effect size [95% CI]
Total pain score	Active	0.48 ± 0.17	0.86	0.29 ± 0.12	<0.001	−0.18	−1.061 [−1.574 to −0.541]	0.22 ± 0.13	<0.001	−0.25	−1.587 [−2.137 to −1.027]
	Placebo	0.47 ± 0.17		0.43 ± 0.13		−0.04		0.43 ± 0.13		−0.04
Superficial pain	Active	5.94 ± 2.37	0.11	4.24 ± 2.15	<0.001	−1.70	−1.059 [−1.571 to −0.539]	3.21 ± 2.07	<0.001	−2.72	−1.651 [−2.207 to −1.086]
	Placebo	6.85 ± 2.18		6.21 ± 1.52		−0.63		6.24 ± 1.56		−0.60
Deep pain	Active	5.79 ± 4.44	0.881	3.68 ± 3.33	0.03	−2.10	−0.562 [−1.052 to −0.067]	2.79 ± 2.86	0.0021	−3.00	−0.841 [−1.342 to −0.334]
	Placebo	6.06 ± 4.45		5.79 ± 4.13		−0.27		5.55 ± 3.66		−0.51
Paroxysmal pain	Active	8.65 ± 4.30	0.911	4.29 ± 3.05	<0.001	−4.36	−0.991 [−1.500 to −0.476]	2.79 ± 2.35	<0.001	−5.86	−1.528 [−2.073 to −0.973]
	Placebo	8.56 ± 4.34		7.55 ± 3.51		−1.02		7.22 ± 3.37		−1.33
Evoked pain	Active	8.99 ± 6.11	0.551	7.02 ± 5.28	0.25	−1.97	−0.283 [−0.768 to 0.203]	6.27 ± 4.82	0.09	−2.72	−0.423 [−0.909 to 0.067]
	Placebo	8.25 ± 5.79		8.51 ± 5.19		0.25		8.39 ± 5.20		0.14
Paraesthesia	Active	8.96 ± 3.02	0.201	4.77 ± 3.00	0.01	−4.18	−0.642 [−1.135 to −0.145]	3.12 ± 2.57	<0.001	−5.83	−1.473 [−2.014 to −0.922]
	Placebo	7.91 ± 3.47		6.77 ± 3.22		−1.14		7.08 ± 2.79		−0.83

Active n = 33, Placebo n = 33. Statistical significance set at P = < 0.05

¹ Shapiro–Wilk distribution test found these data (in one or both arms) to be not normally distributed

Tests of significance are performed nonparametrically with Mann–Whitney U scores given as average ± standard deviation